Ventilatory Threshold and Risk of Pulmonary Exacerbations in Cystic Fibrosis

被引:0
|
作者
Campos, Natalia E. [1 ]
Vendrusculo, Fernanda M. [1 ]
Perez-Ruiz, Margarita [2 ]
Donadio, Marcio V. F. [1 ,3 ,4 ]
机构
[1] Pontificia Univ Catolica Rio Grande do Sul, Infant Ctr, Lab Pediat Phys Act, Porto Alegre, RS, Brazil
[2] Univ Politecn Madrid, Fac Ciencias Act Fis & Deporte, Dept Hlth & Human Performance, Madrid, Spain
[3] Univ Int Catalunya, Fac Med & Ciencias Salud, Dept Physiotherapy, Barcelona, Spain
[4] Ctr Infant, Lab Pediat Phys Act, Av Ipiranga 6690,2 Andar, BR-90610000 Porto Alegre, RS, Brazil
关键词
  cystic fibrosis; pulmonary exacerbation; anaerobic threshold; exercise capacity; prognosis; oxygen consumption; QUALITY-OF-LIFE; HEART-FAILURE; NUTRITIONAL-STATUS; PEAK VO2; CHILDREN; HOSPITALIZATION; STANDARDIZATION; ABNORMALITIES; SPIROMETRY; FREQUENCY;
D O I
10.4187/respcare.10428
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
BACKGROUND: Whereas pulmonary exacerbations and aerobic fitness play a key role in the prognosis of cystic fibrosis (CF), the use of ventilatory threshold data as markers of exacerbation risk has been scarcely addressed. This study sought to examine the association between aerobic fit-ness, assessed through ventilatory threshold variables recorded during cardiopulmonary exercise testing (CPET), and the risk of exacerbations in individuals with CF. METHODS: Participants of this retrospective cohort study were subjects from 6 y of age. Over a 4-y period, the following data were recorded: lung function indicators, CPET variables, time to first exacerbation and an-tibiotic use, along with demographic, clinical, and anthropometric data. RESULTS: The mean age of 20 subjects included was 16 +/- 5.4 y. Univariate regression analysis revealed that lung function (FEV1: Cox hazard ratio [HR] 0.97, P = .03; and forced expiratory flow between 25- 75% of vital capacity [FEF25-75]: Cox HR 0.98, P = .036) and aerobic fitness (oxygen consump-tion [VO2] at ventilatory threshold: Cox HR 0.94, P = .01; and ventilatory equivalent for carbon dioxide [VE/VCO2] at ventilatory threshold: Cox HR 1.13, P = .049) were associated with exacerba-tion risk, whereas in the multivariate model, only VO2 at the ventilatory threshold (%max) (Cox HR 0.92, P = .01) had a significant impact on this risk. Consistently, individuals experiencing exacerba-tion had significantly lower VO2 values (%max) at the ventilatory threshold (P = .050) and higher ventilatory equivalent for oxygen consumption (VE/VO2) (P = .040) and VE/VO2 (P = .037) values at the ventilatory threshold. Time to exacerbation was significantly correlated with VO2 at the ventila-tory threshold (r = 0.50, P = .02), VE/VO2 (r = -0.48, P = .02), and VE/VCO2 (r = -0.50, P = .02). CONCLUSIONS: Our results suggest an association between CPET variables at the ventila-tory threshold and exacerbations. Percentage VO2 at the ventilatory threshold could serve as a complementary variable to monitor exacerbations in people with CF.
引用
收藏
页码:620 / 627
页数:8
相关论文
共 50 条
  • [1] Pulmonary exacerbations in cystic fibrosis
    Stenbit, Antine E.
    Flume, Patrick A.
    CURRENT OPINION IN PULMONARY MEDICINE, 2011, 17 (06) : 442 - 447
  • [2] Acute Pulmonary Exacerbations in Cystic Fibrosis
    Goss, Christopher H.
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 40 (06) : 792 - 803
  • [3] Pulmonary Exacerbations in Children with Cystic Fibrosis
    Waters, Valerie
    Ratjen, Felix
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2015, 12 : S200 - S206
  • [4] Treatment of pulmonary exacerbations in cystic fibrosis
    Ng, Christabella
    Nadig, Tejaswi
    Smyth, Alan R.
    Flume, Patrick
    CURRENT OPINION IN PULMONARY MEDICINE, 2020, 26 (06) : 679 - 684
  • [5] Outpatient management of pulmonary exacerbations in children with cystic fibrosis
    Perrem, Lucy
    Martin, Isaac
    Ratjen, Felix
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2023, 17 (04) : 295 - 304
  • [6] Reproducibility of Spirometry During Cystic Fibrosis Pulmonary Exacerbations
    Sanders, Don B.
    Rosenfeld, Margaret
    Mayer-Hamblett, Nicole
    Stamey, David
    Redding, Gregory J.
    PEDIATRIC PULMONOLOGY, 2008, 43 (11) : 1142 - 1146
  • [7] Risk factors associated with pulmonary exacerbations in pediatric patients with cystic fibrosis
    Lubovich, Silvina
    Zaragoza, Silvina
    Rodriguez, Viviana
    Buendia, Jefferson
    Camargo Vargas, Bethy
    Alchundia Moreira, Jessica
    Galanternik, Laura
    Ratto, Patricia
    Teper, Alejandro
    ARCHIVOS ARGENTINOS DE PEDIATRIA, 2019, 117 (05): : E466 - E471
  • [8] Pulmonary exacerbations in cystic fibrosis
    Rabin, HR
    Butler, SM
    Wohl, MEB
    Geller, DE
    Colin, AA
    Schidlow, DV
    Johnson, CA
    Konstan, MW
    Regelmann, WE
    PEDIATRIC PULMONOLOGY, 2004, 37 (05) : 400 - 406
  • [9] Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis
    Wagener, Jeffrey S.
    Rasouliyan, Lawrence
    VanDevanter, Donald R.
    Pasta, David J.
    Regelmann, Warren E.
    Morgan, Wayne J.
    Konstan, Michael W.
    PEDIATRIC PULMONOLOGY, 2013, 48 (07) : 666 - 673
  • [10] Systemic Corticosteroids in the Management of Pediatric Cystic Fibrosis Pulmonary Exacerbations
    Davis, Chelsea S.
    Faino, Anna, V
    Onchiri, Frankline
    Gibson, Ronald L.
    Merjaneh, Lina
    Ramsey, Bonnie W.
    Rosenfeld, Margaret
    Cogen, Jonathan D.
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2023, 20 (01) : 75 - 82